Alto Neuroscience, Inc. (ANRO)
(Real Time Quote from BATS)
$11.34 USD
+0.03 (0.27%)
Updated Jun 5, 2024 02:22 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANRO 11.34 +0.03(0.27%)
Will ANRO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
Alto Neuroscience announces Michael Hanley as COO
Alto Neuroscience appoints Michael Hanley as COO
Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment